Literature DB >> 2293879

Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.

S Suciu1, R Kuse, H J Weh, D K Hossfeld.   

Abstract

Cytogenetic studies were performed in 120 patients with de novo myelodysplastic syndrome (MDS) classified according to FAB criteria. Twenty-eight patients had refractory anemia (RA), 14 had refractory anemia with ring sideroblasts (RARS), 45 had refractory anemia with blast excess (RAEB), 19 had refractory anemia with blast excess in transformation (RAEB-t), and 14 had chronic myelomonocytic leukemia (CMMoL). Fifty patients (42%) had clonal chromosome anomalies at initial analysis. The most common cytogenetic anomalies were: 5q- (11 patients), trisomy 8 (nine patients), -7/7q- (6 patients), 12p- (five patients), followed by structural anomalies of chromosome 17 (four patients), and loss of Y chromosome (three patients). The prognostic value of chromosome anomalies was examined by comparison of the significance of single chromosome anomalies (34 patients) versus multiple cytogenetic changes (16 patients). Patients with multiple anomalies had a shorter survival (8 months) than patients with single anomalies (18 months) or those with a normal karyotype (36 months). All these differences were significant. The incidence of multiple anomalies was higher in patients with RAEB and RAEB-t than in those with RA, RARS, and CMMOL (p less than 0.05). However, no chromosome anomaly was specifically associated with any group of FAB classification. Transformation to acute leukemia was observed in 25% of patients with normal karyotype, 41% of patients with single anomalies, and 50% of patients with multiple changes. The incidence of leukemic transformation was significantly higher in patients with multiple anomalies than in those with a normal karyotype (p less than 0.05). Thus, in the present study, FAB classification and chromosome anomalies were of independent prognostic significance. Sequential cytogenetic studies were performed in 23 patients to correlate the cytogenetic and clinical findings during the course of the disease. Six of seven patients with transformation to acute leukemia showed a karyotypic evolution. These findings agree with the view that an unstable karyotype can be associated with a poor prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2293879     DOI: 10.1016/0165-4608(90)90193-e

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

1.  A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group.

Authors:  R Willemze; N van der Lely; H Zwierzina; S Suciu; G Solbu; H Gerhartz; B Labar; G Visani; M E Peetermans; A Jacobs
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

Review 2.  Biology and treatment of myelodysplastic syndromes--developments in the past decade.

Authors:  R Willemze; W E Fibbe; J H Falkenburg; J C Kluin-Nelemans; P M Kluin; J E Landegent
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

3.  Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.

Authors:  M Werner; H Maschek; V Kaloutsi; H Choritz; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 4.  Extramedullary myeloid cell tumours localised to the mediastinum: a rare clinicopathological entity with unique karyotypic features.

Authors:  R Nounou; H Al-Zahrani H; D S Ajarim; J Martin; A Iqbal; R Naufal; R Stuart; G Roberts; M Gyger
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

5.  Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.

Authors:  Elias Jabbour; Koichi Takahashi; Xuemei Wang; A Megan Cornelison; Lynne Abruzzo; Tapan Kadia; Gautam Borthakur; Zeev Estrov; Susan O'Brien; Mar Mallo; William Wierda; Sherry Pierce; Yue Wei; Francisco Sole; Rui Chen; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2013-07-23       Impact factor: 10.047

Review 6.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

7.  Cytogenetic findings in 179 patients with myelodysplastic syndromes.

Authors:  D Haase; C Fonatsch; M Freund; B Wörmann; H Bodenstein; H Bartels; B Stollmann-Gibbels; E Lengfelder
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

8.  Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.

Authors:  Mohammad Shahjahani; Elham Homaei Hadad; Shirin Azizidoost; Kowsar Chenani Nezhad; Saeid Shahrabi
Journal:  Oncol Rev       Date:  2019-02-04

9.  Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells.

Authors:  Madhu M Ouseph; Robert P Hasserjian; Paola Dal Cin; Scott B Lovitch; David P Steensma; Valentina Nardi; Olga K Weinberg
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.